Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming.

MarketBeat • 3 hours ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood cells, leading to debilitating anemia SPRING HOUSE, Pa., Feb. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® (nipocalimab-aahu) as the first-ever treatment for patients with warm autoimmune hemolytic anemia (wAIHA).b This rare and serious autoantibody disease affects approximately 1 in 8,000 in the United States and currently has no approved treatments despite substantial unmet need.1 The condition is associated with significant morbidity and mortality, with those living with the disease found to experience a 20-30% higher risk of death.2 "People living with warm autoimmune hemolytic anemia face a serious, life-threatening disease with no approved treatment options and a high risk of complications, including profound chronic fatigue, transfusion dependence, and organ failure," said David M Lee, M.D.

PRNewsWire • 3 hours ago

Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • 9 hours ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.

Reuters • Feb 23, 2026

Does JNJ Stock Still Offer Value?

Up 17% through February 2026, Johnson & Johnson stock (NYSE: JNJ) is riding a wave of momentum fueled by a "triple threat" of high-growth oncology sales, a massive MedTech rebound, and a surprise earnings beat that defied new tariff pressures.

Forbes • Feb 23, 2026

Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.

Zacks Investment Research • Feb 23, 2026

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of New York. The suit follows J&J's refusal to cease and desist its promotion of a scientifically flawed real-world evidence analysis that misinforms healthcare providers and patients in an effort to increase its market share in a concentrated and increasingly competitive prostate cancer treatment market.

Business Wire • Feb 23, 2026

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

Johnson & Johnson is a core player in global healthcare. A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing dividend.

The Motley Fool • Feb 22, 2026

The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson

Johnson & Johnson is a Dividend King. Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years.

The Motley Fool • Feb 22, 2026

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients  78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement) STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.

PRNewsWire • Feb 21, 2026